Key Highlights

  • Tenax Therapeutics' Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed its primary 6-minute walk distance endpoint.
  • The trial also missed the key KCCQ symptom endpoint.
  • Prespecified analyses showed a 49% NT-proBNP reduction and benefit in lower-baseline-walk patients.
  • The program's path forward depends on FDA feedback and a potential enriched registrational path.

Tenax Therapeutics ( Nasdaq : TENX) reported that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed the primary 6-minute walk distance endpoint and key KCCQ symptom endpoint.

What Happened

Prespecified analyses showed biomarker and hemodynamic signals, including a 49% NT-proBNP reduction and benefit in lower-baseline-walk patients, even as the trial's primary endpoints were not met.

NT-proBNP is a widely used biomarker of cardiac stress in heart failure conditions, and a reduction of this magnitude, even absent a primary endpoint win, may support the case for a more targeted patient population in future development.

Market Reaction

The disclosed information does not include stock price or trading data for Tenax Therapeutics following the trial results.

Missed primary endpoints in a Phase 3 cardiopulmonary trial typically introduce substantial uncertainty for a clinical-stage company, since the path to a registrational filing then depends heavily on whether regulators view the secondary and biomarker signals as sufficient to support a narrower approval pathway.

Outlook

The program's path forward is dependent on FDA feedback and an enriched registrational path, leaving the biomarker and hemodynamic signals from the prespecified analyses as the basis for potential further development.